Trial
NCT03622775
Daratumumab in Treating Participants With Relapsed Multiple Myeloma After Stem Cell Transplant
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
M.D. Anderson Cancer Center
Collaborators
Janssen Scientific Affairs, LLC
Condition
Recurrent Plasma Cell Myeloma
Intervention
Daratumumab
Why stopped
\<75% participation
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-04-24